 |
|
|
|
|
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2022 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
NanoString Technologies, Inc.
| | | | | Phone: | (206) 378-NANO | | Fax: | (206) 387-6288 | | Year Established: | 2003 | | Employees: | 90 | | Ticker: | NSTG | | Exchange: | NASDAQ | | Main Contact: | David W. Ghesquiere, Senior VP, Corporate & Business Development | | | | Other Contacts: | Alessandra Cesano, M.D., Ph.D., CMO
Kathy Surace-Smith, VP & General Counsel
J. Chad Brown, Senior VP, Sales & Marketing
Thomas Bailey, CFO
Joseph M. Beechem, Ph.D., Senior VP, R&D
Mary Tedd Allen, Ph.D., Senior VP, Operations
Brad Gray, President & CEO
| | | | Company Description | | NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,000 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology. | |
|
|
|
|
|
|
|
